Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – C-o-group doai
Reexamination Certificate
2006-03-21
2006-03-21
Low, Christopher S. F. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C-o-group doai
C514S874000, C600S007000
Reexamination Certificate
active
07015253
ABSTRACT:
The present invention provides treatment regimens for treating diseased prostate tissue, including the steps of chemically ablating prostate tissue and coadministering an antiandrogen. In some embodiments, prostate tissue is chemically ablated by injection of ethanol, or an injectable gel comprising ethanol, into prostate tissue. Steroidal and non-steroidal antiandrogens are suitable antiandrogens. One suitable non-steroidal antiandrogen is bicalutamide. The treatment regimen is suitable for treatment of prostate tissue diseases including benign prostatic hyperplasia and prostatic carcinoma. The invention further provides a treatment regimen for treating benign prostatic hyperplasia, including the steps of damaging prostate tissue and coadministering an antiandrogen. Also provided by the present invention is a kit for treating a human male, including a means for necrosing prostate tissue, an antiandrogen drug, and a means for administering the antiandrogen drug. A kit including a first surgical device for delivering a chemoablation fluid to prostate tissue transurethrally, an antiandrogen drug such as bicalutamide, and a second surgical device for administering the antiandrogen drug, is further provided.
REFERENCES:
patent: 3847988 (1974-11-01), Gold
patent: 3875229 (1975-04-01), Gold
patent: 4097578 (1978-06-01), Perronnet et al.
patent: 4220735 (1980-09-01), Dieck et al.
patent: 4239776 (1980-12-01), Glen et al.
patent: 4377584 (1983-03-01), Rasmusson et al.
patent: 4386080 (1983-05-01), Crossley et al.
patent: 4461283 (1984-07-01), Doi
patent: 4636505 (1987-01-01), Tucker
patent: 4760071 (1988-07-01), Rasmusson et al.
patent: 5116615 (1992-05-01), Gokcen et al.
patent: 5322503 (1994-06-01), Desai
patent: 5562703 (1996-10-01), Desai
patent: 5630794 (1997-05-01), Lax et al.
patent: 5672171 (1997-09-01), Andrus et al.
patent: 5753641 (1998-05-01), Gormley et al.
patent: 5770603 (1998-06-01), Gibson
patent: 5817649 (1998-10-01), Labrie
patent: 5861002 (1999-01-01), Desai
patent: 5872150 (1999-02-01), Elbrecht et al.
patent: 5994362 (1999-11-01), Gormley et al.
patent: 6022860 (2000-02-01), Engel et al.
patent: 6142991 (2000-11-01), Schatzberger
patent: 6179831 (2001-01-01), Bliweis
patent: 6200573 (2001-03-01), Locke
patent: 6217860 (2001-04-01), Woo et al.
patent: 6231591 (2001-05-01), Desai
patent: 6378525 (2002-04-01), Beyar et al.
patent: 2001/0048942 (2001-12-01), Weisman et al.
patent: 2002/0040220 (2002-04-01), Zvuloni et al.
patent: WO 92/10142 (1992-06-01), None
patent: WO 93/15664 (1993-08-01), None
Zeneca Pharmaceuticals, Professional Information Brochure for Casodex Bicalutamide Tablets, Sep. 2000, 2 pages.
Zeneca Pharmaceuticals, Professional Information Brochure for Zoladex Goserelin Acetate Implant—3-Month, Feb. 1999, 2 pages.
Zeneca Pharmaceuticals, Professional Information Brochure for Zoladex Goserelin Acetate Implant—3.6mg, Feb. 1999, 2 pages.
http://www.cancerbacup.org.uk/info/flutamide.html, CancerBACUP, “Flutamide (Drogenil)”, downloaded Jun. 25, 2001, 3 pages.
http://www.rxmed.com, RxMed, “Anandron”, downloaded Jun. 25, 2001, 4 pages.
http://www.phc.vcu.edu/feature/finasteride/finasteride.html, Schieck, Cynthia L., Finasteride (Propecia), downloaded May 31, 2002, 6 pages.
http://www.merck.com/product/usa/proscar/hcp/prod—att/specificity.html?US—healthcare=yes, Merck & Co., Inc. “DHT Hormone Information at Proscar.com”, downloaded Jun. 5, 2002, 2 pages.
www.merck.com, Merck & Co., Inc., “Physician Prescribing Information—Proscar (Finasteride) Tablets”, downloaded Jun. 25, 2001, 2 pages.
Zincke, Horst et al., “Role of Early Adjuvant Hormonal Therapy After Radical Prostatectomy for Prostate Cancer”, The Journal of Urology, vol. 166, pp. 2208-2215, Dec. 2001.
“The Management of Radiation Failure in Prostate Cancer”,Reviews in Urology, vol. 4, supplement 2, 2002, 35 pages.
“Cryoablation of the Prostate”,Urology, vol. 60, Supplement 2A, Aug. 2002, 58 pages.
Zippe, Craig D., “Cyrosurgery of the Prostate—Techniques and Pitfalls”,The Craft of Urologic Surgery, from the Prostate Center, Department of Urology, Cleaveland Clinic Foundation, Cleveland, Ohio, Urologic Clinics of North America, vol. 23, No. 1, Feb. 1996, pp. 147-163.
P. Derakshani et al., “Cryoablation of Localized Prostate Cancer”, European Urology, vol. 34, pp. 181-187, 1998.
Arie Belldegrun et al, “Society of Urologic Oncology Biotechnology Forum: New Approaches and Targets for Advanced Prostate Cancer”, The Journal of Urology, Oct. 2001, vol. 166: pp. 1316-1321.
Terry Cook et al, “Development of GnRH Antagonists for Prostate Cancer: New Approaches to Treatment”, The Oncologist 2000, vol. 5: pp. 162-168.
John Trachtenberg et al, “A Phase 3, Multicenter, Open Label, Randomized Study of Abarelix Versus Leuprolide Plus Daily Antiandrogen in Men with Prostate Cancer”, The Journal of Urology, Apr. 2002, vol. 167: pp. 1670-1674.
Hans J. Stricker, “Luteinizing Hormone-Releasing Hormone Antagonists in Prostate Cancer”, Elsevier Science Inc., Urology 58: (Supplement 2A), Aug. 2001, pp. 24-27.
Peter Zvara et al, “Ablation of Canine Prostate Using Transurethral Intraprostatic Absolute Ethanol Injection”, Elsevier Science Inc., Urology 54 (3) 1999, pp. 411-415.
Peter Zvara et al, “Ablation of Canine Prostate Using Transurethral Intraprostatic Absolute Ethanol Injection”, Department of Surgery, Division of Urology and Department of Pathology, University of Vermont College of Medicine, dated prior to Jul. 9, 2002, pp. 1-15.
Peter Zvara, M.D., Ph. D. et al, “Ablation of Canine Prostate Using Transurethral Intraprostatic Absolute Ethanol Injection”, Department of Surgery, Division of Urology and Department of Pathology* University of Vermont College of Medicine, www.injectTx.com., 2 pages.
Nobuyuki Goya et al, “Ethanol Injection Therapy of the Prostrate for Benign Prostatic Hyperplasia: Preliminary Report on Application of a New Technique”, The Journal of Urology, Aug. 1999, vol. 162: pp. 383-386.
David A. Levy et al, “Transrectal Ultrasound-Guided Intraprostatic Injection of Absolute Ethanol With and Without Carmustine: A Feasibility Study in the Canine Model”, Elsevier Science Inc, Urology 53, 1999, 7 pages.
Peter J. Littrup, M.D. et al, “Percutaneous Ablation of Canine Prostate Using Transrectal Ultrasound Guidance-Absolute Ethanol and Nd:YAG Laser”, Investigative Radiology, Oct. 1988, vol. 23. pp. 734-739.
Tito Livraghi, M.D. et al, “Long Term Results of Single Session Precutaneous Ethanol Injection in Patients with Large Hepatocellular Carcinoma”, American Cancer Society, Jul. 1998, Cancer, vol. 83(1): pp. 48-57.
Y. Iso et al, “Repeated Injection Selerotherapy is Preferable to Combined Therapy with Variceal Ligation to Avoid Recurrence of Esophageal Varices: A Prospective Randomized Trial”, Hepato-Gastroenterology, (1997), vol. 44: pp. 467-471.
Tito Livraghi, M.D. et al, “Small Hepatocellular Carcinoma: Percutaneous Alcohol Injection-Results in 23 Patients”, Radiology, Aug. 1988, vol. 168 (2): pp. 313-317.
T. Fujisawa et al, “Intratumoral Ethanol Injection for Malignant Tracheobronchial Lesions: A New Broncofiberscopic Procedure”, Endoscopy, 1986, vol. 18: pp. 188-191.
Tito Livraghi, M.D. et al, “US-guided Percutaneous Alcohol Injection of Small Hepatic and Abdominal Tumors”, Radiology, Nov. 1986, vol. 161 (2): pp. 309-312.
Francis A. Burgener, M.D. et al, “Treatment of Experimental Adenocarcinomas by Percutaneous Intratumoral Injection of Absolute Ethonal”, Investigative Radiology, Jun. 1987, vol. 22 (6): pp. 472-475 & 477-478.
R. Uflacker et al, “Ablation of Tumor and Inflammatory Tissue With Absolute Ethanol”, Acta Radiologica Diagnosis 27 (1986), Fasc.: 2, pp. 131-138.
Luigi Solbiati, M.D. et
Escandon M. Alejandro Sousa
Neisz Johann J.
American Medical Systems Inc.
Faegre & Benson LLP
Lewis Amy
Low Christopher S. F.
LandOfFree
Regimen for treating prostate tissue and surgical kit for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Regimen for treating prostate tissue and surgical kit for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Regimen for treating prostate tissue and surgical kit for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3595696